NEVADANANO
18.5.2021 16:51:13 CEST | Business Wire | Press release
NevadaNano, the world’s leading innovator in gas detection sensor technology, today announced it signed three prominent distributors as it continues its expansion throughout Europe. The companies will provide local support and sales to NevadaNano’s growing customer base for its ground-breaking Molecular Property Spectrometer™ (MPS™) flammable gas sensors.
“The addition of these three market-leading companies underscores the demand for an innovative sensor like the MPS, one that redefines the standard after nearly 40 years,” said Gary Collins, General Manager, EMEA for NevadaNano. “We are confident that our novel technology and their deep experience of these companies will help their customers develop leading-edge products with highly accurate and reliable gas detection technology.”
- Maritex Company , based in Gdynia, Poland, is one of the largest, fast-developing wholesalers of electronic equipment on the Polish market. The company supports customers in Poland, Romania, and Sweden.
- Gas Sensor RU is a leading supplier of gas sensing solutions across Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, and Ukraine. The company focuses on securing the environment and people’s safety in the fast-growing industry and world.
- GVZ Components , based in Italy, is a key supplier across Europe in the sensors' market with more than 40 years of experience supplying leading companies in a wide range of applications: from automotive to HVAC-R, from medical to industrial, from military to aerospace.
NevadaNano offers a range of unique gas detection sensors for flammables, refrigerants (A1, A2L and A3’s) and the MPS sensors deliver unprecedented reliability and accuracy. Unlike traditional sensors, the MPS sensors accurately report 0-100% LEL across 19 flammable gases and 6 refrigerant gases with a single factory calibration and no field maintenance over their lifetime. The MPS Flammable Gas sensors’ accuracy is enhanced by integrated, real-time measurements and built-in compensation for temperature, pressure, and humidity. Gas concentration readings are accurate across the full environmental range including rapid environmental transients, delivering best-in-class false-positive accuracy. The company’s MPS sensors are inherently immune to drift, decay, or poison.
For more information contact NevadaNano at info@nevadanano.com
About NevadaNano
NevadaNano's programmable, multi-gas detection technology is the first new approach to flammable gas detection in over 40 years. The MPS technology was developed with the support of DARPA, the DOD, and the Department of Homeland Security for the most challenging gas detection applications and is the winner of the coveted R&D100 award and the Tech Connect National Innovation award. The sensors utilize 24 patented inventions to tackle the toughest chemical analysis tasks. For information visit NevadaNano.com or connect on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom